# Editas Medicine share price today (Editas Medicine, Inc., EDIT)

> Editas Medicine, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. EDIT · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/edit

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $2.72 (+10.1% in a year)
- Revenue (Jun 2026): $11.9 M (+232.3% on a year ago)
- Profit (Jun 2026), incl. one-off: −$18.2 M (one-off item, see below)
- Operating margin: −167.3% (+544.3 points on a year ago)
- ROE: −587%, FY25
- ROIC: −64.8%, against a 15.4% cost of capital: −80.2 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Editas Medicine share price today? Editas Medicine, Inc.'s share price was $2.72 at the close on 4 November 2026. That is 1.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $4, and at that close it sat 51% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 1 year the share price moved −6% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Editas Medicine pay? Editas Medicine, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Editas Medicine on? Editas Medicine is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Editas Medicine profitable? Editas Medicine, Inc. posted a net loss of $18.2 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $160 M. That loss is 153.3% of the quarter's revenue. The same quarter a year earlier lost $53.2 M. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −$18.2 M it is bigger than the quarter's whole revenue of $11.9 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −167.3% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Editas Medicine make, and is it growing? Editas Medicine, Inc. reported $11.9 M of revenue in the Jun 2026 quarter, +232.3% on the same quarter a year earlier. Over 4 years it has grown 12.2% a year on average. The last full year, FY25, came in at $40.5 M. The last four reported quarters add to $47.0 M. FY25 revenue was $40.5 M, +25.4% on the year before. Recent pace: the last four quarters grew +3,109.9% on average, against 12.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +20.8%, against −16.3% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Editas Medicine keep? Editas Medicine, Inc.'s operating margin was −167.3% in the Jun 2026 quarter, 544.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between −1,146.3% and −216.6%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +544.3 percentage points on the year while gross margin changed +282.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Editas Medicine's profit turning into cash? Editas Medicine, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $165 M of cash, against −$160 M of profit. After $607 K of spending on assets, free cash was −$166 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Editas Medicine's cash go? Editas Medicine, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $14.2 M on assets over the last 3 years. Averaged over those years that is 11.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $14.2 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Editas Medicine's P/E ratio, and how does it compare with its own history? Editas Medicine, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Editas Medicine, Inc. at 10.3× its FY25 revenue of $40.5 M. The P/E comes back here once profit turns positive. ## Is the Editas Medicine business getting better or worse? Editas Medicine, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Editas Medicine earn on its capital? Editas Medicine, Inc. earned a ROE of −587% in FY25. Its return on capital used (ROIC) is 80.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −395.0% net margin and 0.22× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −395.0% net margin × 0.22× asset turnover × 6.84× leverage (assets divided by equity) ≈ −594.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −64.8% − 15.4% = −80.2 percentage points. The 15.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Editas Medicine have too much debt? Editas Medicine, Inc. has total debt of $15.5 M against shareholder equity of $105 M as of Jun 2026, so its debt is 0.15× its equity, which is very little. Year by year, that ratio went from 0.05 in FY21 to 0.66 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Editas Medicine shareholding pattern? 33.1% of Editas Medicine, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 11.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Editas Medicine from balance-sheet trouble? For Editas Medicine, Inc., the Z-score is −8.85. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −8.85 is inside the danger zone, so the balance sheet is a real risk. ## How does Editas Medicine rank in its industry? There is no score against its industry: Editas Medicine, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Editas Medicine compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Editas Medicine in size? Editas Medicine is the 153rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: CorMedix Inc., Prothena Corporation plc and Prelude Therapeutics Incorporated. Just below it: Altimmune, Inc., Allogene Therapeutics, Inc. and Assembly Biosciences, Inc. ### Biotechnology companies close in size

1. [CorMedix Inc.](https://www.sectoralpha.in/us/stocks/crmd) $441 million
2. [Prothena Corporation plc](https://www.sectoralpha.in/us/stocks/prta) $431 million
3. [Prelude Therapeutics Incorporated](https://www.sectoralpha.in/us/stocks/prld) $420 million
4. Editas Medicine, Inc. $418 million
5. [Altimmune, Inc.](https://www.sectoralpha.in/us/stocks/alt) $412 million
6. [Allogene Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/allo) $411 million
7. [Assembly Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/asmb) $405 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Phoenix Asia Holdings Limited](https://www.sectoralpha.in/us/stocks/phoe) $402 million · Engineering & Construction
2. [Once Upon A Farm, PBC](https://www.sectoralpha.in/us/stocks/ofrm) $400 million · Packaged Foods
3. Editas Medicine, Inc. $399 million
4. [Repay Holdings Corporation](https://www.sectoralpha.in/us/stocks/rpay) $399 million · Software - Infrastructure
5. [G. Willi-Food International Ltd.](https://www.sectoralpha.in/us/stocks/wilc) $398 million · Food Distribution

## What else do people ask about Editas Medicine? ### What were Editas Medicine's latest quarterly results? Editas Medicine, Inc. reported revenue of $11.9 M and a net loss of $18.2 M for the Jun 2026 quarter. Earnings per share were −$0.15. The operating margin was −167.3%, 544.3 percentage points higher than a year earlier (as of 4 November 2026). ### What is Editas Medicine's market cap? Editas Medicine, Inc.'s market capitalisation is $418 M at a stock price of $2.72. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Editas Medicine performing? Editas Medicine, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Editas Medicine's stock price go up? This page does not forecast Editas Medicine, Inc.'s stock price. What it shows instead: the stock price is $2.72. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Editas Medicine in its business cycle? Editas Medicine, Inc.'s FY25 operating margin was −245.2%, against a 5-year range of −1,146.3% to −216.6%: the middle of its own range, neither a peak nor a low. The latest quarter was −167.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Editas Medicine story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Editas Medicine a stock worth studying right now? What the numbers show: Editas Medicine, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.